We know how important timely coverage for new drugs is. As one part of the drug reimbursement process, the pCPA is committed to supporting timely drug coverage for people in Canada.
That’s why we’re looking to improve and add to our negotiation pathway options by refreshing existing processes and introducing a new pathway for specific cancer drugs. These expedited negotiation pathways include the Early Negotiation Process (ENP), the Targeted Negotiation Process (TNP), and the pCPA Temporary Access Process (pTAP).
Previously, we engaged with clinicians, patient groups, and industry on pTAP when it was developed in 2023. We’re now requesting feedback on the ENP and the TNP to ensure we’re developing options that will work for our partners in the pharmaceutical ecosystem.
You’re invited to learn about the ENP and the TNP before completing our online survey below.
Have your say
We would appreciate your feedback on our upcoming expedited negotiation pathways. Please take a moment to review the details of the ENP and the TNP, then complete the online survey below by Wednesday, November 12.